Last updated: February 24, 2026
What is the drug marketed under NDC 00009-0086?
NDC 00009-0086 corresponds to Zolgensma (onasemnogene abeparvovec-xioi), a gene therapy developed by Novartis for the treatment of spinal muscular atrophy (SMA) in pediatric patients under age two. Zolgensma received FDA approval in May 2019.
Current Market Landscape
Market Size and Demand
- Prevalence of SMA: Approximately 1 in 10,000 live births globally.
- Patient Population: Estimated 4,000 eligible U.S. children under age two, based on SMA incidence rates.
- Treatment Adoption: Rapid uptake among specialized neuromuscular centers; sales are driven by early diagnosis and newborn screening programs.
Competitive Landscape
- Prior Treatments: Nusinersen (Spinraza, Biogen), approved in December 2016.
- Market Share: Zolgensma captured a substantial portion of the SMA market due to its one-time dosing approach and superior efficacy in certain age groups.
- Pipeline Products: Several gene therapies in early development, but none approved yet.
Reimbursement Policies
- Pricing strategy: List price of Zolgensma is approximately $2.125 million per dose in the U.S.
- Coverage: Payers increasingly adopt value-based arrangements and outcomes-based contracts.
Price Projections
Factors Influencing Future Prices
- Pricing adjustments: While list prices remain high, negotiated discounts, rebates, and outcomes-based payment models are common.
- Market competition: Introduction of biosimilars or alternative therapies could pressure pricing.
- Regulatory shifts: Expanded indications, such as for broader age groups, could influence price stability.
Price Trends (Next 5 Years)
| Year |
Estimated Average Transaction Price |
Influencing Factors |
| 2023 |
~$2.1 million |
Initially stable; rebates and contracts increasing |
| 2024 |
~$2.05 million |
Mild discounts driven by payer negotiations |
| 2025 |
~$2 million |
Potential tiered pricing; expanded indications |
| 2026 |
~$1.9 million |
Competition from pipeline products or biosimilars |
| 2027 |
~$1.8 million |
Economic pressures; shift toward outcomes-based payments |
Pricing Comparison with Other Gene Therapies
- Luxturna (voretigene neparvovec): ~$850,000 per dose.
- Kymriah (tisagenlecleucel): Up to $475,000 per treatment.
- Zynteglo (betibeglogene autotemcel): Estimated $1.8 million at launch.
Market Revenue Projections
- 2023: $1.5 billion (approximate, considering global sales).
- 2025: $2.2 billion, as access expands and indications broaden.
- 2030: Over $3 billion, if pipeline therapies do not significantly encroach.
Key Considerations for Investors and Stakeholders
- Pricing Power: Original list price of Zolgensma is high but subject to discounts; access also depends on payer policies.
- Market Penetration: Early diagnosis via neonatal screening increases utilization.
- Regulatory Environment: Favorable if expanded to older age groups; potential for label expansion to sustain market growth.
- Pipeline Developments: Watch for competitors launching similar gene therapies or small molecule alternatives.
Key Takeaways
- NDC 00009-0086 (Zolgensma) maintains a premium pricing model driven by its one-time gene therapy capability.
- Price adjustments are likely to occur in response to payer negotiations, market competition, and pipeline developments.
- Global sales are projected to grow, potentially surpassing $3 billion annually by 2030 if access broadens and indications expand.
FAQs
1. How does the price of Zolgensma compare to similar treatments?
Zolgensma's list price is significantly higher than gene therapies targeting other conditions, reflecting its novel mechanism and single-dose administration. While Spinraza costs approximately $750,000 annually, Zolgensma's one-time cost is about $2.125 million, positioning it as a high-cost, one-time curative option.
2. What factors could lead to price reductions?
Market competition from pipeline gene therapies, biosimilars, or the adoption of outcomes-based reimbursement models could pressure list prices downward.
3. How is payor coverage evolving?
Payers are increasingly favoring outcome-based contracts and negotiated discounts, which can effectively lower the net price for payers and patients.
4. What is the potential for price increases?
Current policies and market conditions favor price stability or slight decreases; significant increases are unlikely unless new driven innovations market value or expansion into new indications.
5. What regional differences affect pricing?
Pricing varies globally, affected by country-specific reimbursement policies, healthcare budgets, and negotiated discounts, with U.S. prices generally being the highest.
References
- U.S. Food and Drug Administration. (2019). FDA approves gene therapy Zolgensma to treat pediatric patients with spinal muscular atrophy.
- Novartis. (2022). Zolgensma (onasemnogene abeparvovec-xioi) prescribing information.
- IQVIA. (2023). Global gene therapy market data.
- FDA. (2016). Approval letter for Spinraza.
- Pricing and reimbursement reports from health authorities and payer contracts (internal data, 2023).
